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Abstract
Background: Probiotics are used to provide health benefits. The present study tested the effect of a probiotic
yoghurt on faecal output of beta-defensin and immunoglobulin A in a group of young healthy women eating a
defined diet.
Findings: 26 women aged 18-21 (median 19) years residing in a hostel were given 200 ml normal yoghurt every
day for a week, followed by probiotic yoghurt containing Bifidobacterium lactis Bb12
® (10
9 in 200 ml) for three
weeks, followed again by normal yoghurt for four weeks. Stool samples were collected at 0, 4 and 8 weeks and
assayed for immunoglobulin A and human beta-defensin-2 by ELISA. All participants tolerated both normal and
probiotic yoghurt well. Human beta-defensin-2 levels in faeces were not altered during the course of the study. On
the other hand, compared to the basal sample, faecal IgA increased during probiotic feeding (P = 0.0184) and
returned to normal after cessation of probiotic yoghurt intake.
Conclusions: Bifidobacterium lactis Bb12
® increased secretory IgA output in faeces. This property may explain the
ability of probiotics to prevent gastrointestinal and lower respiratory tract infections.
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Introduction
Probiotic foods are widely used to promote health. They
are also sometimes used to prevent or treat specific gas-
trointestinal illnesses. Recent studies have shown that
ingestion of foods containing probiotic Lactobacillus or
Bifidobacterium strains prevent or reduce morbidity
from enteric infections and lower respiratory tract infec-
tions [1,2]. Bifidobacterium lactis strain Bb12
® is a pro-
biotic microbe that is widely consumed in the form of
probiotic yoghurt. Probiotic yoghurt containing this
microbe is reported to have beneficial effects on meta-
bolism including lowered serum LDL-cholesterol in
patients with type 2 diabetes,[3] increased HDL choles-
terol in adult women [4] and improved glucose
tolerance during pregnancy [5,6]. Bb12
® administration
has also been shown to increase faecal secretory IgA
excretion in preterm infants [7]. The health claims of
probiotics have been demonstrated with varying levels
of evidence, with only a few being substantiated using
double blind randomized controlled trials.
Dietary practices in India are different from that in the
developed countries where evidence of probiotic efficacy
has been gathered. This, together with the occurrence of
frequent gastrointestinal infections in childhood and the
widespread consumption of home-made yoghurt in the
diet, may result in differences in the gastrointestinal
response to probiotic bacteria in Indians. The present
study evaluated the effect of daily ingestion of yoghurt
containing Bifidobacterium lactis Bb12
® on faecal excre-
tion of IgA and b-defensin 2 in healthy adult southern
Indian women volunteers.
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Participants and Interventions
Healthy young adult women living in a hostel and eating
food prepared in the hostel kitchen were recruited for
the study. Individuals who had received a course of anti-
biotics within the last month were excluded as were
those who intended to travel out of the city during the
course of the feeding trial. Participants were briefed
about the nature and purpose of the study, the impor-
tance of compliance with the study intervention, and the
importance of maintaining a daily record of bowel
movements and any abdominal symptoms. Volunteers
were given a small monetary incentive to participate in
the study. All participants received normal yoghurt daily
for the first week of the feeding study, following which
they received probiotic yoghurt daily for the next three
weeks. This was again followed by regular yoghurt feed-
ing for the next four weeks. Normal yoghurt was pre-
pared in the diet kitchen by boiling standardized toned
milk (3.0% fat & 8.5% msnf) and then cooling to 40°C,
following which starter culture (YCX-11, Chr Hansen)
was added at 1 unit per 10 litres of milk. The milk was
distributed in 200 ml cups which were incubated at 40°
C until the pH reached 4.6, and cups then transferred to
a refrigerator for cooling. Probiotic yoghurt was pre-
pared by adding Bb-12
® (Batch no 2927446, Chr Han-
sen) at a concentration of 0.0006% to the cultured milk
prepared as above. This dosage was calculated to pro-
vide approximately 10
9 cfu of Bifidobacterium per 200
ml serving of yoghurt. The investigator responsible for
providing the diluted starter culture did not participate
in yoghurt distribution or in the laboratory analyses.
Bifidobacterial concentrations in yoghurt were checked
by culture of diluted yoghurt (1:10 in peptone water
broth, 0.9% NaCl, 0.85% peptone) and serial dilutions
(10
-2 to 10
-10) were made and plated on Reinforced
Clostridial Agar (13.5 g/250 ml, pH 6.8) (Himedia
laboratories, Mumbai, India, Catalog number-M154-
500G) containing mupirocin (25 μg/L of medium) (RM-
6090, Himedia laboratories, Mumbai, India). Plates were
incubated at 37°C in anaerobic jars for three days and
colony counts calculated from the growth in serial
dilutions.
Yoghurt was prepared fresh every morning and dis-
tributed at lunch time to the participants. As all partici-
pants had lunch in the hostel mess, this allowed
distribution at a single point and consumption of
yoghurt under supervision. The study was preceded by
focus group discussions. Participants were interviewed
by a social worker and a dietician. Demographic data
were recorded and socioeconomic score was calculated
[8]. A 24 hour dietary recall, together with a food fre-
quency questionnaire of commonly used foods over the
past three months, was used to calculate nutrient intake
using standard tables of the composition and nutritive
value of Indian foods [9]. Standard cups and spoons
were used to measure meal sizes. Each participant was
given a printed study diary and asked to record on a
daily basis the following - stool frequency, stool consis-
tency, abdominal pain, gaseousness, and any other
symptoms that the participant noted during this period.
Each participant was requested to give a fresh sample of
stool before the study commenced, at the end of the
first intervention period (i.e. at 4 weeks) and at the end
of the second intervention period (i.e. at 8 weeks). The
study protocol, incentive, and consent forms were
approved by the Institutional Review Board. All partici-
pants provided written consent.
Fresh samples of stool were collected in the morning
and transported immediately to the laboratory and
stored at -80°C. Secretory IgA and beta-defensin 2 were
assayed by ELISA (K8870 and K6500, Immunodiagnos-
tik, Germany) following manufacturer’s instructions.
Stool samples weighing 80-120 mg were diluted with
appropriate amounts of buffer provided in the kit to
give constant dilutions, vortexed, and centrifuged at
13000 rpm for 5 minutes in 1.5 ml tubes. Supernatants
were diluted 1:250 in wash buffer. Standards, controls
and stool samples were simultaneously run in the ELISA
and the concentration of secretory IgA and b-defensin 2
were read against a standard curve and expressed as
concentration per gram wet weight of stool.
Statistics
Values are presented as numbers for categorical vari-
ables and as median with interquartile range for contin-
uous data. Analysis of significance of differences
between groups was done using paired t tests comparing
each group with the others.
Results
26 women of median age 19 (range 18-21) years were
recruited for the study. Their median (range) socioeco-
nomic score was 16 (13-25). A score of 11-15 is categor-
ized as middle class and 16-25 as upper middle class).
Their median (range) height was 154 (150-171) cm,
weight was 53.5 (43-77) kg, and BMI was 22.1. (18.5-
26.3). The dietary intakes and preferences were as fol-
lows. Eight were lacto-vegetarian, while the rest ate
meat at least once a week. Their median (range) daily
nutrient intake was energy 1425 (1025-1735) kcal, pro-
tein 30 (20-40) g, fat 19 (16-26) g, simple carbohydrates
17 (14-45) and complex carbohydrates 246 (143-336).
No significant change in bowel frequency (median
daily frequency 1) or stool consistency was reported
during consumption of the probiotic yoghurt. There was
no significant complaint of abdominal pain or bloating
or other abdominal symptoms during probiotic yoghurt
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volunteers each had abdominal pain during probiotic
yoghurt feeding and normal yoghurt feeding. 13 and 8
participants respectively had symptoms consistent with
a common cold during three weeks of probiotic or nor-
mal yoghurt feeding.
Figure 1 shows the b-defensin 2 concentrations in
faeces of volunteers fed probiotic yoghurt or normal
yoghurt. There was no change in the concentration of
this immune effector molecule brought about by the
ingestion of probiotics. On the other hand, faecal levels
of secretory IgA were significantly higher in the partici-
pants during the probiotic yoghurt feeding period com-
pared to basal periods (P = 0.0184). Faecal IgA levels
after cessation of probiotic yoghurt feeding showed a
trend towards being increased compared to the baseline
levels (P = 0.0822) and was not significantly different
from the peak levels observed during probiotic yoghurt
feeding (P = NS) (Figure 1).
Discussion
This study in a group of young adult women in south
India shows that the probiotic yoghurt was well toler-
ated and that faecal excretion of secretory immunoglo-
bulin A was significantly increased during feeding of
probiotic yoghurt compared to the baseline. Although
the levels decreased after probiotic yoghurt was stopped,
they did not return to normal and tended to be higher
than baseline levels. This suggests that the effect of the
probiotic yoghurt persisted even after cessation of feed-
ing this; there is also be a possibility that normal
yoghurt contributed to elevated faecal sIgA, that was
more pronounced during feeding of probiotic yoghurt.
These results are likely to be generalizable. Studies in
healthy children and preterm infants have shown an
increase in faecal IgA excretion in response to probiotic
interventions [7,10]. A study in animals showed that
probiotic yoghurt containing Lactobacillus casei
increased IgA secretion in mice [11]. On the other
hand, a study in infants did not find any change in fae-
cal IgA after probiotic administration [12]. In another
study, faecal IgA output in pre-term infants was
increased in response to both mother’sm i l ka n dt of e r -
mented formula (in which the probiotic was killed by
heating) [13].
Probiotics are also known to upregulate defensin
expression and to increase defensin secretion from
intestinal epithelium. Both lactobacilli and probiotic E.
coli have been shown to increase human beta-defensin 2
(hBD-2) secretion from CaCo-2 cells through stimula-
tion of TLR2 and TLR5 respectively [14-16]. In a feed-
ing trial in healthy adult volunteers, the probiotic E. coli
Nissle strain increased fecal hBD-2 excretion in healthy
adult volunteers [17]. In the present study, there was no
obvious effect on faecal hBD-2 excretion during the pro-
biotic yoghurt feeding period. Thus far, an effect on
human beta-defensin expression has been noted only
with lactobacilli and with E. coli Nissle 2. In a study
where 11 lactobacilli were tes t e d ,o n l y2o ft h es t r a i n s
increased hBD-2 mRNA expression in CaCo-2 cells. The
difference between lactobacilli strains in their ability to
induce hBD-2 correlated with the presence of genes
encoding glycosylated cell surface structures [18].
Although we did not examine the probiotic used in this
study for these genes, this appears a likely explanation
for the absence of an effect on hBD-2 excretion in stool.
This study had several drawbacks. It was a non-rando-
mised study and the participants could potentially
Figure 1 Box and whiskers plots showing the effect of
probiotic yoghurt containing Bifidobacterium lactis Bb12
® on
faecal excretion of secretory IgA and human beta-defensin-2.
The middle line represents the median, the box represents the
interquartile range and the whiskers represent the total range.
Faecal IgA excretion significantly increased during after probiotic
yoghurt feeding and returned to normal levels after cessation of the
probiotic.
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on the basis of smell and taste, although the nature of
t h et w ow a sn o tk n o w nt ot h e m .T h e s ew e r en o tc o m -
mercially available standardized products, although we
took care to make them to a standard protocol. The
generalizability of these results to other products and
populations is therefore not to be assumed.
The present study appears to be the first report of an
effect of probiotic foods on faecal IgA in healthy adults.
Increased IgA output was noted only with yoghurt con-
taining Bb12
® and not with normal yoghurt. An increase
in faecal IgA may explain the ability of probiotics to
prevent diarrhoeal illness in specific settings. It is possi-
ble that this may also explain beneficial effects of pro-
biotics in preventing severe lower respiratory tract
infections.
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